Vonafexor Market Size, Forecast, and Emerging Insight - 2032

"Vonafexor Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about Vonafexor for Non-alcoholic Steatohepatitis (NASH) in the seven major markets. A detailed picture of the Vonafexor for NASH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Vonafexor for NASH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Vonafexor market forecast analysis for NASH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in NASH.

Drug Summary:

Vonafexor (EYP001) is an orally bioavailable synthetic non-steroidal, non-bile acid FXR agonist small molecule also developed in NASH. Most KOL agrees that FXR agonists could become the backbone of future NASH therapies. It has demonstrated its efficacy in a stelic mouse model STAM with a significant positive impact on most NASH key parameters (fibrosis, steatosis, inflammation, ballooning, triglycerides, and NAS). It differentiates from other FXR agonists with a unique chemistry and PK PD profile to possibly provide a best-in-class therapeutic index.

Vonafexor (EYP001) is currently evaluated in a Phase IIa clinical trial in patients with advanced NASH, i.e., a fibrosis Stage F2 or F3. After the interim safety analysis showed good tolerance, the independent DSMC suggested pursuing the trial to completion as planned. The company conducts three Phase II trials with its lead compound Vonafexor in Chronic Hepatitis B and NASH.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Vonafexor description, mechanism of action, dosage and administration, research and development activities in Non-alcoholic Steatohepatitis (NASH).
• Elaborated details on Vonafexor regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Vonafexor research and development activities in NASH across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Vonafexor.
• The report contains forecasted sales of Vonafexor for NASH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for NASH.
• The report also features the SWOT analysis with analyst views for Vonafexor in NASH.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Vonafexor Analytical Perspective by DelveInsight

• In-depth Vonafexor Market Assessment

This report provides a detailed market assessment of Vonafexor for Non-alcoholic Steatohepatitis (NASH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• Vonafexor Clinical Assessment

The report provides the clinical trials information of Vonafexor for Non-alcoholic Steatohepatitis (NASH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Non-alcoholic Steatohepatitis (NASH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Vonafexor dominance.
• Other emerging products for NASH are expected to give tough market competition to Vonafexor and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Vonafexor in NASH.
• Our in-depth analysis of the forecasted sales data of Vonafexor from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Vonafexor in NASH.

Key Questions:

• What is the product type, route of administration and mechanism of action of Vonafexor?
• What is the clinical trial status of the study related to Vonafexor in Non-alcoholic Steatohepatitis (NASH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Vonafexor development?
• What are the key designations that have been granted to Vonafexor for NASH?
• What is the forecasted market scenario of Vonafexor for NASH?
• What are the forecasted sales of Vonafexor in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Vonafexor for NASH?
• Which are the late-stage emerging therapies under development for the treatment of NASH?